<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Drug hypersensitivity: Classification and clinical features</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Drug hypersensitivity: Classification and clinical features</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Drug hypersensitivity: Classification and clinical features</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Werner J Pichler, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">N Franklin Adkinson, Jr, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anna M Feldweg, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 30, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Drug hypersensitivity reactions (DHR) include allergic, exaggerated pharmacologic, and pseudoallergic reactions to medications that result from an enhanced immunologic or inflammatory response.</p><p>The classification and clinical features of drug hypersensitivity will be reviewed here, beginning with a categorization of the different types of adverse drug reactions. A detailed discussion of the pathogenesis of drug hypersensitivity and an approach to the diagnosis and management of these conditions are found separately. (See  <a class="medical medical_review" href="/z/d/html/2072.html" rel="external">"Drug allergy: Pathogenesis"</a> and  <a class="medical medical_review" href="/z/d/html/2079.html" rel="external">"An approach to the patient with drug allergy"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">CATEGORIES OF ADVERSE DRUG REACTIONS</span><span class="headingEndMark"> — </span>An adverse drug reaction is a general term referring to any untoward reaction to a medication. Adverse drug reactions may be broadly divided into two types, type A and type B  (<a class="graphic graphic_table graphicRef51797" href="/z/d/graphic/51797.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H109975714"><span class="h2">Type A reactions</span><span class="headingEndMark"> — </span>Type A reactions make up 85 to 90 percent of all adverse drug reactions. These can affect any individual, given sufficient dose and exposure, and are predictable from the known pharmacologic properties of a drug. Examples of type A reactions include diarrhea in response to antibiotics, gastritis in association with long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs), or aminoglycoside nephrotoxicity.</p><p class="headingAnchor" id="H109975726"><span class="h2">Type B reactions</span><span class="headingEndMark"> — </span>Type B reactions represent hypersensitivity reactions. They make up 10 to 15 percent of adverse drug reactions, occur in a susceptible subgroup of patients, and have signs and symptoms that are different from the pharmacologic actions of the drug. The great majority of hypersensitivity reactions are mediated by immunologic and/or inflammatory mechanism. In addition, there are reactions, referred to as idiosyncratic drug reactions and exaggerated sensitivity reactions, which present with symptoms that do not involve the immune system or inflammatory cells.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug hypersensitivity reactions (DHR)</strong> are the result of immune or inflammatory cell stimulations by the medication. They account for about 6 to 10 percent of all adverse drug reactions, but up to 10 percent of fatal reactions [<a href="#rid1">1</a>]. Hypersensitivity reactions are the focus of this review.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Idiosyncratic drug reactions and exaggerated sensitivity</strong> – Idiosyncratic drug reactions are qualitatively distinct from the known pharmacologic toxicities of the drug. These reactions can arise from genetic differences in the patient, such as <a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">primaquine</a> causing nonimmune hemolytic anemia in patients with glucose-6-phosphate dehydrogenase deficiency or <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a> toxicity developing in patients with thiopurine methyltransferase (TPMT) deficiency [<a href="#rid2">2-4</a>]. Other patients experience an <strong>exaggerated sensitivity</strong> at low and sometimes subtherapeutic doses. An example would be the individual who develops tinnitus in response to a single dose of <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>. This putatively reflects altered drug metabolism or increased end-organ sensitivity. (See  <a class="medical medical_review" href="/z/d/html/7104.html" rel="external">"Drug-induced hemolytic anemia"</a>.) </p><p></p><p class="headingAnchor" id="H508647128"><span class="h3">Definition of drug hypersensitivity reactions</span><span class="headingEndMark"> — </span>DHRs may be defined as reactions resulting from unintended and unwanted stimulation of immune or inflammatory cells by a medication.</p><p class="headingAnchor" id="H8"><span class="h1">CLASSIFICATION OF DRUG HYPERSENSITIVITY</span><span class="headingEndMark"> — </span>Drug hypersensitivity can be subdivided based on time of appearance of symptoms, mode of action of the drug on immune/inflammatory cells, or on immunologic mechanism. In practice, a drug hypersensitivity reaction (DHR) is often defined by a combined approach, considering time of appearance, possible mode of action (mechanism of immune stimulation), and resulting pathophysiology [<a href="#rid5">5</a>].</p><p>It is important to differentiate between DHRs elicited by small molecules used as medications and DHRs induced by large proteins used as medications (eg, monoclonal antibodies), because the modes of action and resulting adverse reactions differ substantially [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H363716466"><span class="h2">Based on timing of symptom onset</span><span class="headingEndMark"> — </span>The World Allergy Organization (WAO) has recommended dividing immunologic drug reactions into immediate reactions (ie, onset within one hour of exposure) and delayed reactions (onset after one hour), based on the timing of the appearance of symptoms [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H3527817740"><span class="h3">Immediate</span><span class="headingEndMark"> — </span>The WAO distinction between immediate and delayed drug reactions is intended to distinguish IgE-mediated, type I reactions from other types. Type I reactions classically begin within one hour of the first administered dose. However, some IgE-mediated reactions appear after one hour, particularly if the drug was administered orally and with food, which slows absorption. Nevertheless, this period of one hour identifies the majority of IgE-mediated reactions, which carry the risk of anaphylaxis if the patient is reexposed.</p><p class="headingAnchor" id="H848292582"><span class="h3">Delayed</span><span class="headingEndMark"> — </span>Reactions appearing after one hour are classified as delayed, although most delayed reactions begin after six hours and typically after days of treatment. As an example, delayed reactions to <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">amoxicillin</a> classically start on day 7 to 10 of treatment, and may even begin one to three days after cessation of treatment. These reactions may be caused by several different mechanisms, but they are not IgE mediated. Types II, III, and IV immunologic reactions are all considered delayed reactions.</p><p>Some delayed reactions begin after weeks of continuous treatment. One such disorder is "drug rash with eosinophilia and systemic symptoms" (DRESS), which is a systemic drug reaction that begins 1 to 12 weeks into continuous treatment [<a href="#rid8">8</a>]. This reaction, which is also called "drug-induced hypersensitivity syndrome" (DiHS), is characterized by fever, rash, and multiorgan involvement, and may or may not be associated with eosinophilia and lymphocytosis. The liver (hepatitis) and heart (hypersensitivity myocarditis) may be affected. These reactions can persist for weeks to months, even after the medication is stopped. (See <a class="local">'Type IV reactions'</a> below and  <a class="medical medical_review" href="/z/d/html/4933.html" rel="external">"Myocarditis: Causes and pathogenesis", section on 'Hypersensitivity myocarditis'</a>.)</p><p class="headingAnchor" id="H1686873146"><span class="h2">Based on mode of action</span><span class="headingEndMark"> — </span>Drugs, which are small molecular compounds, often with a size &lt;1000 Daltons, can interact with the immune and inflammatory system in different ways:</p><p class="headingAnchor" id="H1622726398"><span class="h3">Drug allergy/immune reactions</span><span class="headingEndMark"> — </span>Most drugs are chemicals that are too small to elicit immune responses. However, some drugs have or gain the ability to bind covalently to proteins, which can transform a self-protein to a new antigen (hapten protein or hapten-peptide complex). Such hapten-protein complexes act like classical antigens and thus elicit immune reactions to the hapten-modified protein/peptide, which can be mediated by IgE, IgG, or by lymphocytes. These reactions can result in the many different clinical pictures of drug allergy (eg, contact dermatitis to 1-chloro-2,4-dinitrobenzene (DNCB), IgE-mediated anaphylaxis to penicillin). The different types of immunologic drug reactions are described below. (See <a class="local">'Based on immunologic mechanism'</a> below.)</p><p class="headingAnchor" id="H2586950216"><span class="h3">Pharmacologic interaction with immune receptors (p-i reactions)</span><span class="headingEndMark"> — </span>A substantial part of immune-mediated DHR is due to an "off-target" activity of a drug on immune receptor proteins, such as HLA proteins and T cell receptors (TCR). These interactions are called "pharmacologic interaction with immune receptors," or p-i reactions. P-i mediated immune stimulations do not result from the drug acting as a new antigen. Rather, the drug forms a strong, noncovalent bond directly with the immune receptor on antigen presenting cells (HLA) or on T cells (TCR), leading to stimulation of the T cell [<a href="#rid9">9,10</a>]. The stimulation may be either direct, if it binds to TCR, or indirect, if the drug binds to the HLA-protein and thereby elicits a T cell reaction directed to the drug-modified HLA-protein-peptide complex. Thus, in all p-i reactions, the clinical symptoms are due to activation of T cells and the effects of that activation on the involved cells. The clinical picture can be maculopapular eruption, SJS/TEN, DRESS, hepatitis, etc. As p-i reactions are typical pharmacologic drug-receptor interactions, they are dose-dependent to some degree.</p><p>If the drug binds preferentially to a certain HLA-protein (eg, <a class="drug drug_general" data-topicid="8993" href="/z/d/drug information/8993.html" rel="external">abacavir</a> to HLA-B*57:01), then the reactions disproportionately or exclusively affect individuals with these alleles [<a href="#rid11">11</a>]. This explains the HLA-linkage of some DHRs and means that certain p-i mediated forms of DHR are predictable. Well-investigated examples of p-i reactions occur with abacavir, <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a>, <a class="drug drug_general" data-topicid="8439" href="/z/d/drug information/8439.html" rel="external">allopurinol</a>, <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">dapsone</a>, and flucloxacillin hypersensitivity reactions. HLA testing of patients is recommended before administering abacavir and carbamazepine in populations in which there is a significant prevalence of the genotype. Specific screening recommendations are discussed in more detail separately. (See <a class="local">'Drug-induced hypersensitivity syndrome'</a> below and  <a class="medical medical_review" href="/z/d/html/2221.html" rel="external">"Antiseizure medications: Mechanism of action, pharmacology, and adverse effects", section on 'Carbamazepine'</a>.)</p><p class="headingAnchor" id="H3934459907"><span class="h3">Pseudoallergy</span><span class="headingEndMark"> — </span>Another heterogeneous form of adverse drug reaction is drug intolerance or pseudoallergy [<a href="#rid12">12,13</a>].<strong> </strong>Pseudoallergic reactions resemble immunologic drug reactions but lack evidence of specific immune system involvement (drug-specific IgE, IgG, or specifically activated T cells)  (<a class="graphic graphic_table graphicRef79967" href="/z/d/graphic/79967.html" rel="external">table 2</a>). The pathomechanism of these reactions is only partly understood [<a href="#rid14">14</a>]. The signs and symptoms of most pseudoallergic reactions are similar to IgE-mediated (immediate) allergic reactions. Both appear rapidly (within minutes), and both can involve urticaria, angioedema, or anaphylaxis due to mast cell degranulation. In pseudoallergy due to NSAIDs, there is both mast cell activation and eosinophilic inflammation. Pseudoallergic reactions to NSAIDs are reviewed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/2082.html" rel="external">"NSAIDs (including aspirin): Allergic and pseudoallergic reactions"</a>.)</p><p class="headingAnchor" id="H22248197"><span class="h2">Based on immunologic mechanism</span><span class="headingEndMark"> — </span>Historically, immunologic reactions, whether caused by drugs, infections, or autoimmune processes, have been divided into four categories (I to IV) according to the Gell and Coombs system  (<a class="graphic graphic_table graphicRef80466" href="/z/d/graphic/80466.html" rel="external">table 3</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Type I – Immediate in onset and mediated by IgE and mast cells and/or basophils.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Type II – Delayed in onset and caused by antibody (usually IgG) mediated cell destruction.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Type III – Delayed in onset and caused by IgG:drug immune complex deposition and complement activation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Type IV – Delayed in onset and T cell mediated. Of note, this classification was established before a detailed analysis of T cell subsets and functions was technically possible. As new immunologic tools were developed, type IV reactions were further subdivided into types IVa, IVb, IVc, and IVd  (<a class="graphic graphic_figure graphicRef75626" href="/z/d/graphic/75626.html" rel="external">figure 1</a>) [<a href="#rid15">15</a>]. (See <a class="local">'Subcategories of type IV'</a> below.)</p><p></p><p>Medications cause types I and IV reactions far more commonly than types II and III, which usually follow prolonged, higher dose therapy. Most medications cause just one type, although certain drugs, such as penicillin, can induce all four types.</p><p class="headingAnchor" id="H2142386496"><span class="h1">TYPES OF IMMUNOLOGIC DRUG REACTIONS</span></p><p class="headingAnchor" id="H13"><span class="h2">Type I reactions</span><span class="headingEndMark"> — </span>Type I reactions require the presence of drug-specific IgE. A small minority of patients form drug-specific IgE upon exposure to a medication, while most do not even with prolonged treatment.</p><p>Once formed, drug-specific IgE occupies surface receptors on mast cells and basophils throughout the body. If the drug is encountered again, it (or its metabolite) may bind to these IgE molecules, causing crosslinking of the receptors and activation of the cells, resulting in symptoms. IgE-mediated reactions are dose dependent, although this may not be clinically apparent because even very low doses they can cause severe systemic symptoms.</p><p class="headingAnchor" id="H14"><span class="h3">Clinical features</span><span class="headingEndMark"> — </span>The signs and symptoms of type I reactions are directly attributable to the vasoactive mediators released by mast cells and basophils. The most common signs and symptoms are urticarial rash  (<a class="graphic graphic_picture graphicRef75230" href="/z/d/graphic/75230.html" rel="external">picture 1</a> and <a class="graphic graphic_picture graphicRef72519" href="/z/d/graphic/72519.html" rel="external">picture 2</a>); pruritus; flushing; angioedema of the face, extremities, or laryngeal tissues (leading to throat tightness with stridor, or rarely asphyxiation); wheezing; gastrointestinal symptoms; and/or hypotension.</p><p>Anaphylaxis is the most severe presentation of an IgE-mediated drug reaction. Mast cell tryptase and histamine can be elevated in the circulation in the first several hours after anaphylaxis, and the detection of these mediators implicates mast cells and basophils in the reaction, supporting the diagnosis of anaphylaxis. (See  <a class="medical medical_review" href="/z/d/html/392.html" rel="external">"Anaphylaxis: Emergency treatment"</a> and  <a class="medical medical_review" href="/z/d/html/389.html" rel="external">"Laboratory tests to support the clinical diagnosis of anaphylaxis"</a>.)</p><p>The presence of urticaria is useful in identifying IgE-mediated reactions, because the classical wheal and flare are hallmark signs of mast cell degranulation. However, other skin findings in drug reactions can mimic urticaria and it can be difficult to discern if a rash was truly urticarial based on history alone. Many delayed reactions involve a pruritic exanthem or rash that causes diffuse swelling of the skin, and affected patients will report raised, itchy areas of skin. However, these delayed-onset edematous exanthems are NOT urticarial rashes. In addition, they are generally not dangerous, provided the skin does not blister or slough and there are no signs of organ inflammation. Reactions involving rash and organ inflammation are discussed below. Conversely, urticarial rashes may be altered in appearance or suppressed by ongoing antihistamine therapies, such that in such patients the absence of urticaria should not be taken as evidence against anaphylaxis. (See <a class="local">'Type IV reactions'</a> below.)</p><p>Neither fever nor elevations in serum C-reactive protein are seen with IgE-mediated reactions. The absence of these features can help distinguish IgE-mediated reactions from some other adverse drug reactions.</p><p class="headingAnchor" id="H15"><span class="h3">Timing</span><span class="headingEndMark"> — </span>The timing of onset of type I reactions is rapid, but varies with the clinical setting and presentation. IgE-mediated reactions occur rapidly after the last administered dose, which underlies the designation of immediate by the World Allergy Organization (WAO). The time to onset is influenced by the route of administration; intravenously administered medications may cause symptoms in seconds to minutes, while the same drug administered orally may cause symptoms in 3 to 30 minutes if taken on an empty stomach, and in 10 to 60 minutes if taken with food.</p><p class="bulletIndent1"><span class="glyph">●</span>IgE-mediated anaphylactic reactions should NOT begin several days into a course of therapy, if the patient's exposure to the drug has been continuous. However, if several doses are skipped, symptoms can appear when the drug is resumed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Urticaria appearing within minutes to hours after drug intake can also be seen in "pseudoallergic" reactions. (See <a class="local">'Pseudoallergic reactions'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Isolated urticarial skin eruptions can occur late during continuous therapy:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The delayed appearance of urticarial rashes with known allergenic drugs like beta-lactam antibiotics may reflect time required for significant IgE responses, (similar to late-occurring serum sickness reactions).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Urticaria appearing one to two weeks after therapy, and accompanied by arthralgias and fever suggests serum sickness. (See <a class="local">'Pseudoallergic reactions'</a> below and <a class="local">'Serum sickness'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Urticarial eruptions, often appearing days after start of therapy, sometimes also have maculopapular features. These urticarial rashes typically occur with drugs that rarely cause acute allergy (eg, macrolide antibiotics), and are unlikely to be IgE mediated. T cells may also be involved, although the pathogenesis is not known.</p><p></p><p class="headingAnchor" id="H16"><span class="h3">Commonly-implicated drugs</span><span class="headingEndMark"> — </span>The drugs most commonly implicated in type I reactions include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Beta-lactam drugs (penicillins and cephalosporins). (See  <a class="medical medical_review" href="/z/d/html/2073.html" rel="external">"Penicillin allergy: Immediate reactions"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Neuromuscular blocking agents. (See  <a class="medical medical_review" href="/z/d/html/2077.html" rel="external">"Perioperative anaphylaxis: Clinical manifestations, etiology, and management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Quinolones – Quinolone antibiotics have been implicated as a common cause of hypersensitivity reactions in Europe, but less commonly in the United States, so there may be important geographical variations that will become more apparent over time [<a href="#rid16">16</a>]. Only some of these reactions are IgE mediated [<a href="#rid17">17,18</a>]. (See  <a class="medical medical_review" href="/z/d/html/83728.html" rel="external">"Hypersensitivity reactions to fluoroquinolones"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Platinum-containing chemotherapeutic agents, such as <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> and <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">oxaliplatin</a>. (See  <a class="medical medical_review" href="/z/d/html/2835.html" rel="external">"Infusion reactions to systemic chemotherapy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Foreign proteins, including chimeric antibodies, such as <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> and <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>. The frequency with which these agents cause anaphylaxis can also vary by geographical location (eg, cetuximab-induced anaphylaxis was initially reported mostly in the southern United States). (See  <a class="medical medical_review" href="/z/d/html/2811.html" rel="external">"Infusion-related reactions to therapeutic monoclonal antibodies used for cancer therapy"</a>.)</p><p></p><p class="headingAnchor" id="H17"><span class="h3">Previous exposure to the suspect drug</span><span class="headingEndMark"> — </span>IgE-mediated reactions generally require previous exposure to the drug in question. However, the absence of a known prior exposure does not exclude an IgE-mediated reaction, because sensitization may have occurred from exposure to a cross-reactive compound, even though the patient showed no signs of allergy to the sensitizing product.</p><p>The following examples illustrate this phenomenon:</p><p class="bulletIndent1"><span class="glyph">●</span>A significant percentage of patients experiencing anaphylaxis upon first exposure to neuromuscular blocking agents are believed to have been previously sensitized through the use of various cosmetics, personal products, and nonprescription cough remedies (eg, pholcodine in Norway) that contain tertiary and quaternary ammonium groups [<a href="#rid19">19-21</a>]. The ammonium groups shared by all of these agents are highly immunoreactive and can induce cross-reactive IgE antibodies. (See  <a class="medical medical_review" href="/z/d/html/2077.html" rel="external">"Perioperative anaphylaxis: Clinical manifestations, etiology, and management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some patients develop anaphylaxis to <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> and appear to have been previously sensitized to oligosaccharides present on the drug [<a href="#rid22">22</a>]. The same oligosaccharides are found on several nonprimate mammalian proteins, such as beef, pork, and lamb. The source of the original sensitization is still uncertain, although bites of certain tick species have been implicated. (See  <a class="medical medical_review" href="/z/d/html/2393.html" rel="external">"Allergy to meats", section on 'Alpha-gal'</a> and  <a class="medical medical_review" href="/z/d/html/2811.html" rel="external">"Infusion-related reactions to therapeutic monoclonal antibodies used for cancer therapy", section on 'Cetuximab'</a>.)</p><p></p><p class="headingAnchor" id="H18"><span class="h2">Type II reactions</span><span class="headingEndMark"> — </span>Type II reactions are uncommon and involve antibody-mediated cell destruction. Type II reactions may arise when drugs bind to surfaces of certain cell types and act as antigens. Subsequent binding of antibodies to the cell surface results in the cells being targeted for clearance by macrophages. Type II reactions may involve complement activation, but this is variable.</p><p>Clinical manifestations require the presence of high titers of preformed drug-specific IgG (or rarely IgM) antibodies, which are only made by a small percentage of individuals and usually in the setting of high-dose, long-term, or recurrent drug exposure. The factors predisposing individuals to form these antibodies are not fully understood.</p><p class="headingAnchor" id="H19"><span class="h3">Clinical features and timing</span><span class="headingEndMark"> — </span>Type II drug reactions usually present as hemolytic anemia, thrombocytopenia, or neutropenia, since these are the cell types that are most often affected.</p><p>The clinical presentation can vary widely in severity; patients may be asymptomatic or present with fulminant illness. Symptoms usually appear at least five to eight days after exposure, but may begin after much longer periods of treatment. Symptoms can start within hours if the causative drug is stopped and then restarted.</p><p class="headingAnchor" id="H19047356"><span class="h3">Specific presentations</span><span class="headingEndMark"> — </span>Specific manifestations depend on the cell type involved:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug-induced hemolytic anemia</strong> – Hemolytic anemia may present with dyspnea, varying degrees of fatigue, pallor, jaundice, dark urine, splenomegaly, or signs and symptoms of the hyperdynamic state, such as bounding pulses, palpitations, and "roaring in the ears."</p><p></p><p class="bulletIndent1">The drugs most commonly implicated in hemolytic anemia are cephalosporins, penicillins, nonsteroidal anti-inflammatory drugs (NSAIDs), and quinine-quinidine. The evaluation and diagnosis of drug-induced hemolytic anemia are discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/7076.html" rel="external">"Diagnosis of hemolytic anemia in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug-induced thrombocytopenia</strong> – Thrombocytopenia typically presents with petechial bleeding in the skin and buccal mucosa and isolated thrombocytopenia, often severe (ie, &lt;20,000/microL) in a patient taking one or several medications. There may be splenomegaly and hepatomegaly due to platelet sequestration in these organs.</p><p></p><p class="bulletIndent1">Drugs implicated in thrombocytopenia include heparin, abciximab, <a class="drug drug_general" data-topicid="9847" href="/z/d/drug information/9847.html" rel="external">quinine</a> and <a class="drug drug_general" data-topicid="9846" href="/z/d/drug information/9846.html" rel="external">quinidine</a>, sulfonamides, <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a>, gold compounds, beta-lactam antibiotics, <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a>, NSAIDs, and others. This evaluation and diagnosis of this disorder are reviewed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/6674.html" rel="external">"Drug-induced immune thrombocytopenia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug-induced neutropenia or agranulocytosis</strong> – Severe neutropenia or agranulocytosis due to type II drug reactions presents days to weeks after beginning the medication, often with acute and clinically apparent symptoms of infection, such as fever, stomatitis, pharyngitis, pneumonia, or sepsis. Rechallenge or inadvertent subsequent administration is associated with a prompt recurrence, even with low doses.</p><p></p><p class="bulletIndent1">Culprit drugs include <a class="drug drug_general" data-topicid="9830" href="/z/d/drug information/9830.html" rel="external">propylthiouracil</a> (PTU), the antimalarial drug amodiaquine and one of its major metabolites, mono-desethyl amodiaquine, and <a class="drug drug_general" data-topicid="8449" href="/z/d/drug information/8449.html" rel="external">flecainide</a>. The evaluation and diagnosis of this disorder are presented separately. (See  <a class="medical medical_review" href="/z/d/html/8374.html" rel="external">"Drug-induced neutropenia and agranulocytosis"</a>.)</p><p></p><p class="headingAnchor" id="H20"><span class="h2">Type III reactions</span><span class="headingEndMark"> — </span>Type III reactions are mediated by antigen-antibody complexes and usually present as serum sickness, vasculitis, or drug fever. These reactions are uncommon and usually seen in the context of high-dose, prolonged drug administration, similar to type II reactions.</p><p>In a type III reaction, the drug (including biologicals) is believed to act as a soluble antigen. In this capacity, the drug binds drug-specific IgG, forming small immune complexes that can activate complement and precipitate in various tissues, including blood vessels, joints, and renal glomeruli. These immune complexes bind to Fc-IgG receptors of inflammatory cells and/or activate complement, and an inflammatory response ensues. Re-exposure to similar or higher doses of the same drug can cause a more rapid and severe recurrence.</p><p class="headingAnchor" id="H21"><span class="h3">Timing</span><span class="headingEndMark"> — </span>Signs and symptoms take one or more weeks to develop after drug exposure, since significant quantities of antibody are needed to generate symptoms related to antigen-antibody complexes.</p><p class="headingAnchor" id="H22"><span class="h3">Clinical presentation</span><span class="headingEndMark"> — </span>Type III reactions can take several forms:</p><p class="headingAnchor" id="H23"><span class="h4">Serum sickness</span><span class="headingEndMark"> — </span>Classic serum sickness involves fever, urticarial or purpuric rash, arthralgias, and/or acute glomerulonephritis. Alternatively, just one or two of these features may be apparent. Other findings include lymphadenopathy, low serum complement levels, and an elevated erythrocyte sedimentation rate. Serum sickness is a complication of several antitoxins, including those for rabies, botulism, and venoms. (See  <a class="medical medical_review" href="/z/d/html/2078.html" rel="external">"Serum sickness and serum sickness-like reactions"</a>.)</p><p class="headingAnchor" id="H24"><span class="h4">Vasculitis</span><span class="headingEndMark"> — </span>Drug-induced hypersensitivity vasculitis typically presents as palpable purpura and/or petechiae, fever, urticaria, arthralgias, lymphadenopathy, elevated erythrocyte sedimentation rate, and low complement levels. Purpuric lesions often affect the lower extremities. Uncommonly, other organs are involved, such as the gastrointestinal tract or kidneys. The most common culprits are penicillins, cephalosporins, sulfonamides (including most loop and thiazide-type diuretics), <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a>, and <a class="drug drug_general" data-topicid="8439" href="/z/d/drug information/8439.html" rel="external">allopurinol</a>. (See  <a class="medical medical_review" href="/z/d/html/8241.html" rel="external">"Overview of cutaneous small vessel vasculitis"</a>.)</p><p class="headingAnchor" id="H19206921"><span class="h4">Arthus reaction</span><span class="headingEndMark"> — </span>An Arthus reaction is a localized type III hypersensitivity reaction in which antibody-antigen complexes that fix complement are deposited in the walls of small blood vessels, causing acute inflammation, infiltration of neutrophils, and localized skin necrosis. Arthus reactions were initially described in hyperimmunized laboratory animals. Whether significant local reactions to booster doses of modern vaccines are true Arthus reactions has not been demonstrated conclusively. Typically, such reactions present as painful local swelling and erythema beginning within a few hours and usually peaking by 24 hours at sites of booster injections of a vaccine. This type of reaction has been reported with tetanus, diphtheria, and hepatitis B vaccines [<a href="#rid23">23-25</a>].</p><p class="headingAnchor" id="H26"><span class="h2">Type IV reactions</span><span class="headingEndMark"> — </span>Type IV reactions are not mediated by antibodies, in contrast to the other three types above. Type IV drug reactions involve the activation and expansion of T cells, which requires time (normally many hours or days after antigen exposure), hence the name delayed-type hypersensitivity (DTH). In some cases, other cell types (eg, macrophages, eosinophils, or neutrophils) are also involved. Type IV reactions can take many different forms, which vary in significance from inconvenient to life threatening.</p><p class="headingAnchor" id="H24384193"><span class="h3">Timing of type IV reactions</span><span class="headingEndMark"> — </span>Type IV reactions are typically delayed in onset by at least 48 to 72 hours and sometimes by days to weeks following exposure to the culprit drug. On rechallenge, symptoms may appear within 24 hours. The time to symptom onset for reactions depends in part on the number of T cells activated by the drug. These responses are polyclonal, and symptoms appear rapidly if the drug stimulates a large number of different T cell clones. In contrast, a drug that activates just a few clones may not cause clinical symptoms until these T cells have proliferated for several weeks.</p><p>Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) and drug rash with eosinophilia and systemic symptoms/drug-induced hypersensitivity syndrome (DRESS/DiHS), the most dangerous of the delayed drug hypersensitivity reactions, often appear after weeks of uncomplicated treatment, at which point patients suddenly develop signs and symptoms of a fulminant immune reaction. This presentation results from uncontrolled expansion of oligoclonal T cells that have been massively stimulated by the drug, reminiscent of superantigen-like stimulation [<a href="#rid26">26</a>]. (See  <a class="medical medical_review" href="/z/d/html/2091.html" rel="external">"Stevens-Johnson syndrome and toxic epidermal necrolysis: Pathogenesis, clinical manifestations, and diagnosis"</a>.)</p><p class="headingAnchor" id="H2650914"><span class="h3">Subcategories of type IV</span><span class="headingEndMark"> — </span>T cells can orchestrate different forms of inflammation depending on the cytokines produced and the other types of cells that become involved, leading to the subcategories of types IVa to IVd  (<a class="graphic graphic_figure graphicRef75626" href="/z/d/graphic/75626.html" rel="external">figure 1</a>) [<a href="#rid15">15</a>]. These subcategories are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/2072.html" rel="external">"Drug allergy: Pathogenesis"</a>.)</p><p class="headingAnchor" id="H27"><span class="h3">Clinical presentations</span><span class="headingEndMark"> — </span>Reactions involving T cells have prominent skin findings, because the skin is a repository for an enormous number of T cells [<a href="#rid27">27</a>]. Many cutaneous T cells are primed memory-effector cells, which react rapidly if immunogenic agents penetrate the skin barrier or diffuse into the skin from the circulation [<a href="#rid28">28</a>].</p><p>Recognized patterns of cutaneous involvement include the following:</p><p class="headingAnchor" id="H28"><span class="h4">Contact dermatitis</span><span class="headingEndMark"> — </span>Contact dermatitis is a reaction to topically applied drugs, which is characterized by erythema and edema with vesicles or bullae that often rupture, leaving a crust [<a href="#rid29">29</a>]. Subacute and chronic contact dermatitis are characterized by lichenification, erythema, and scaling  (<a class="graphic graphic_picture graphicRef71913" href="/z/d/graphic/71913.html" rel="external">picture 3</a>). (See  <a class="medical medical_review" href="/z/d/html/1731.html" rel="external">"Allergic contact dermatitis in children"</a> and  <a class="medical medical_review" href="/z/d/html/13656.html" rel="external">"Common allergens in allergic contact dermatitis"</a>.)</p><p class="headingAnchor" id="H29"><span class="h4">Maculopapular (including morbilliform) eruptions</span><span class="headingEndMark"> — </span>Maculopapular eruptions are one of the most common forms of delayed drug reactions and may arise from type IV immunologic reactions, as well as from other mechanisms  (<a class="graphic graphic_picture graphicRef70062" href="/z/d/graphic/70062.html" rel="external">picture 4</a>). They are often called "rashes," a term which includes exanthems with varying degrees of cell infiltrations and thus papular component ("maculopapular"). (See  <a class="medical medical_review" href="/z/d/html/15762.html" rel="external">"Exanthematous (maculopapular) drug eruption"</a>.)</p><p class="headingAnchor" id="H365390648"><span class="h4">SDRIFE</span><span class="headingEndMark"> — </span>"Symmetrical drug-related intertriginous and flexural exanthem" (SDRIFE), formerly called baboon syndrome, is a distinctive drug eruption that typically develops within a few hours to days of drug exposure and presents with demarcated, V-shaped erythema in the gluteal/perianal or inguinal/perigenital areas, often with involvement of at least one other flexural area, such as the axillae, elbows, or knees  (<a class="graphic graphic_picture graphicRef86506" href="/z/d/graphic/86506.html" rel="external">picture 5</a>). (See  <a class="medical medical_review" href="/z/d/html/15762.html" rel="external">"Exanthematous (maculopapular) drug eruption", section on 'Intertriginous and flexural reaction pattern'</a>.)</p><p>Some forms of SDRIFE may be related to neurophilic inflammations, such as acute generalized exanthematous pustulosis (AGEP). (See <a class="local">'Acute generalized exanthematous pustulosis'</a> below.)</p><p class="headingAnchor" id="H1934501"><span class="h4">Acute generalized exanthematous pustulosis</span><span class="headingEndMark"> — </span>AGEP is a rare type of reaction characterized by superficial pustules, usually appearing within 24 hours after the administration of the culprit drug  (<a class="graphic graphic_picture graphicRef56807" href="/z/d/graphic/56807.html" rel="external">picture 6</a> and <a class="graphic graphic_picture graphicRef68610" href="/z/d/graphic/68610.html" rel="external">picture 7</a>). Antimicrobial drugs (<a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">amoxicillin</a>), antimalarials, and calcium channel blockers are the most frequently reported triggers of AGEP. This disorder is discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/15761.html" rel="external">"Acute generalized exanthematous pustulosis (AGEP)"</a>.)</p><p class="headingAnchor" id="H103355145"><span class="h4">Drug fever</span><span class="headingEndMark"> — </span>Fever can be the sole symptom or the most prominent symptom of drug hypersensitivity, accompanied in a minority of cases by nonurticarial rash or other organ involvement. Medications implicated in causing drug fever include <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a>, <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">sulfasalazine</a>, <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a>, <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a>, <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a>, and <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>. Patients with active HIV infection or cystic fibrosis appear to be at particular risk, with higher rates of drug fever to antiretroviral drugs and <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a>, respectively [<a href="#rid30">30</a>]. (See  <a class="medical medical_review" href="/z/d/html/2738.html" rel="external">"Drug fever", section on 'Hypersensitivity'</a>.)</p><p class="headingAnchor" id="H30"><span class="h4">Stevens-Johnson syndrome and toxic epidermal necrolysis</span><span class="headingEndMark"> — </span>Severe blistering dermatitides, such as SJS and TEN, are potentially life-threatening reactions characterized by fever and mucocutaneous lesions leading to necrosis and sloughing of the epidermis  (<a class="graphic graphic_picture graphicRef66134" href="/z/d/graphic/66134.html" rel="external">picture 8</a> and <a class="graphic graphic_picture graphicRef67632" href="/z/d/graphic/67632.html" rel="external">picture 9</a> and <a class="graphic graphic_picture graphicRef68682" href="/z/d/graphic/68682.html" rel="external">picture 10</a>). (See  <a class="medical medical_review" href="/z/d/html/2091.html" rel="external">"Stevens-Johnson syndrome and toxic epidermal necrolysis: Pathogenesis, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/2092.html" rel="external">"Stevens-Johnson syndrome and toxic epidermal necrolysis: Management, prognosis, and long-term sequelae"</a>.)</p><p class="headingAnchor" id="H31"><span class="h4">Drug-induced hypersensitivity syndrome</span><span class="headingEndMark"> — </span>DiHS, also called DRESS, is a severe drug hypersensitivity reaction involving rash, fever (38 to 40°C) and multiorgan failure. The liver, kidneys, heart, and/or lungs are most often affected in DiHS/DRESS. It is discussed briefly here and reviewed in more detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/16420.html" rel="external">"Drug reaction with eosinophilia and systemic symptoms (DRESS)"</a>.)</p><p>Debate is ongoing about the most accurate name for this syndrome, as only about 70 percent of cases show peripheral eosinophilia (eg, those caused by <a class="drug drug_general" data-topicid="8993" href="/z/d/drug information/8993.html" rel="external">abacavir</a> or <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">lamotrigine</a> typically do not). The presence of atypical lymphocytes (activated CD8+) is a more consistent finding, which may persist for months after drug withdrawal.</p><p>Drugs that have been implicated in causing DRESS/DiHS include several antiepileptics (including <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a>, <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a>, <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">lamotrigine</a>, and <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a>), <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a>, <a class="drug drug_general" data-topicid="8439" href="/z/d/drug information/8439.html" rel="external">allopurinol</a>, <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">dapsone</a>, <a class="drug drug_general" data-topicid="8993" href="/z/d/drug information/8993.html" rel="external">abacavir</a>, and <a class="drug drug_general" data-topicid="9694" href="/z/d/drug information/9694.html" rel="external">nevirapine</a>.</p><p class="headingAnchor" id="H24384075"><span class="h5">HLA associations</span><span class="headingEndMark"> — </span>Some DiHS/DRESS reactions occur more frequently in patients with certain human leukocyte antigen (HLA) types, since the drugs have been shown to bind to the certain HLA-allele itself predominantly (eg <a class="drug drug_general" data-topicid="8439" href="/z/d/drug information/8439.html" rel="external">allopurinol</a>/oxypurinol to the HLA-B*58:01) or exclusively (<a class="drug drug_general" data-topicid="8993" href="/z/d/drug information/8993.html" rel="external">abacavir</a> and HLA-B*57:01) [<a href="#rid31">31</a>], a phenomenon that is also seen in SJS and TEN. Specific examples include:</p><p class="bulletIndent1"><span class="glyph">●</span>DiHS/DRESS and SJS/TEN to <a class="drug drug_general" data-topicid="8439" href="/z/d/drug information/8439.html" rel="external">allopurinol</a> is associated with HLA-B*58:01 [<a href="#rid32">32</a>]. This B*58:01 association is less stringent in Caucasians (approximately 60 percent), in whom other alleles are also involved in SJS/TEN due to allopurinol [<a href="#rid33">33</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>DiHS/DRESS, and in some cases SJS/TEN, to <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a> disproportionately affects several groups.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Han Chinese patients with HLA-B15:02 [<a href="#rid34">34</a>], as well as Thai, Malaysian, and Indian patients with this same allele [<a href="#rid35">35-37</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Japanese and European patients with HLA-A*31:01 [<a href="#rid38">38,39</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>DiHS/DRESS to <a class="drug drug_general" data-topicid="8993" href="/z/d/drug information/8993.html" rel="external">abacavir</a> occur exclusively in patients with HLA-B*57:01; milder reactions to this drug are not associated with a certain HLA-allele.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">Dapsone</a> hypersensitivity syndrome disproportionately affects Chinese patients with HLA-B*13:01 [<a href="#rid40">40</a>].</p><p></p><p>Once a patient has been identified as having a high-risk HLA profile, family members of that patient should also be advised to avoid the relevant drug, as familial occurrence of such hypersensitivity reactions has been noted. Recommendations have been made for screening patients for specific alleles prior to administration of <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a>, <a class="drug drug_general" data-topicid="9467" href="/z/d/drug information/9467.html" rel="external">oxcarbazepine</a>, <a class="drug drug_general" data-topicid="8993" href="/z/d/drug information/8993.html" rel="external">abacavir</a>, and <a class="drug drug_general" data-topicid="8439" href="/z/d/drug information/8439.html" rel="external">allopurinol</a> [<a href="#rid41">41</a>]. (See  <a class="medical medical_review" href="/z/d/html/2091.html" rel="external">"Stevens-Johnson syndrome and toxic epidermal necrolysis: Pathogenesis, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/3779.html" rel="external">"Abacavir hypersensitivity reaction", section on 'Screening prior to abacavir exposure'</a> and  <a class="medical medical_review" href="/z/d/html/2221.html" rel="external">"Antiseizure medications: Mechanism of action, pharmacology, and adverse effects", section on 'Carbamazepine'</a> and  <a class="medical medical_review" href="/z/d/html/2221.html" rel="external">"Antiseizure medications: Mechanism of action, pharmacology, and adverse effects", section on 'Oxcarbazepine'</a>.)</p><p class="headingAnchor" id="H24384103"><span class="h5">Single organ involvement</span><span class="headingEndMark"> — </span>Occasionally with T cell mediated hypersensitivity, organ involvement occurs in the absence of skin findings, or skin findings are minor and overlooked. Presentations include isolated, drug-induced hepatitis, isolated interstitial nephritis, and isolated pneumonitis. As examples, flucloxacillin, as well as the combination drug <a class="drug drug_general" data-topicid="8676" href="/z/d/drug information/8676.html" rel="external">amoxicillin-clavulanate</a> potassium, may elicit cholestatic hepatitis, while <a class="drug drug_general" data-topicid="8439" href="/z/d/drug information/8439.html" rel="external">allopurinol</a> can cause nephritis [<a href="#rid42">42</a>], and <a class="drug drug_general" data-topicid="8993" href="/z/d/drug information/8993.html" rel="external">abacavir</a> and <a class="drug drug_general" data-topicid="9704" href="/z/d/drug information/9704.html" rel="external">nitrofurantoin</a> can cause pneumonitis. Identification of this presentation as drug allergy can be challenging. These disorders are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3568.html" rel="external">"Drugs and the liver: Metabolism and mechanisms of injury", section on 'Immune-mediated'</a> and  <a class="medical medical_review" href="/z/d/html/3571.html" rel="external">"Drug-induced liver injury"</a> and  <a class="medical medical_review" href="/z/d/html/7234.html" rel="external">"Clinical manifestations and diagnosis of acute interstitial nephritis", section on 'Drugs'</a> and  <a class="medical medical_review" href="/z/d/html/4371.html" rel="external">"Nitrofurantoin-induced pulmonary injury"</a>.)</p><p class="headingAnchor" id="H34"><span class="h3">Association with viral infections</span><span class="headingEndMark"> — </span>There is a higher risk of several type IV drug allergic reactions (ranging from simple exanthema to SJS/TEN) during generalized viral infections and exacerbations of autoimmune diseases, disorders in which T cell reactivity is enhanced by widespread immune activation of T cells, high cytokine levels, and an increased expression of major histocompatibility complex (MHC) and costimulatory molecules.</p><p>Viral infections that predispose patients to reactions to certain drugs include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Epstein Barr virus (with <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">amoxicillin</a>). (See  <a class="medical medical_review" href="/z/d/html/8283.html" rel="external">"Clinical manifestations and treatment of Epstein-Barr virus infection"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cytomegalovirus (with antibiotics) [<a href="#rid43">43</a>]. (See  <a class="medical medical_review" href="/z/d/html/8289.html" rel="external">"Epidemiology, clinical manifestations, and treatment of cytomegalovirus infection in immunocompetent adults", section on 'CMV mononucleosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Human herpes virus 6 (with anticonvulsants and other agents). (See  <a class="medical medical_review" href="/z/d/html/5969.html" rel="external">"Human herpesvirus 6 infection in children: Clinical manifestations, diagnosis, and treatment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>HIV infection (with <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> and other agents). (See  <a class="medical medical_review" href="/z/d/html/3703.html" rel="external">"Fever and rash in patients with HIV", section on 'Drug reactions'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In young children, treatment with <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">amoxicillin</a> (and to a lesser extent with other antibiotics) often elicits exanthematous reactions. Most of these children tolerate the same drug if given again later on [<a href="#rid44">44</a>]. It is likely that systemic viral infections are facilitating these reactions as well, although this has not been conclusively demonstrated. Rhinoviruses, which cause only local infections of the nasopharynx and respiratory tract, are unlikely to have this effect because they do not stimulate the immune system to the same degree. (See  <a class="medical medical_review" href="/z/d/html/100191.html" rel="external">"Penicillin allergy: Delayed hypersensitivity reactions", section on 'Relationship with viral infections'</a>.)</p><p></p><p class="headingAnchor" id="H12276329"><span class="h3">Impact of dose and duration of treatment</span><span class="headingEndMark"> — </span>Dose seems to play an important role in developing delayed hypersensitivity reactions. Most delayed drug hypersensitivity reactions occur to drugs which are given in daily doses of 100 to 1000 mg. <a class="drug drug_general" data-topicid="8439" href="/z/d/drug information/8439.html" rel="external">Allopurinol</a> and <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">lamotrigine</a> are two examples [<a href="#rid45">45-47</a>]. In contrast, drugs that are dosed lower than 10 mg daily are rarely involved in delayed hypersensitivity reactions.</p><p>In <a class="drug drug_general" data-topicid="8439" href="/z/d/drug information/8439.html" rel="external">allopurinol</a> hypersensitivity, there are clinical and in vitro data to suggest that starting dose may also be relevant for developing hypersensitivity [<a href="#rid45">45,46</a>]. Thus, for drugs such as allopurinol or <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">lamotrigine</a>, lower initial doses may lower the incidence of hypersensitivity. (See  <a class="medical medical_review" href="/z/d/html/1672.html" rel="external">"Pharmacologic urate-lowering therapy and treatment of tophi in patients with gout", section on 'Allopurinol'</a>.)</p><p>Length of treatment also appears to be a factor, as more than 10 days of <a class="drug drug_general" data-topicid="8760" href="/z/d/drug information/8760.html" rel="external">gemifloxacin</a> caused maculopapular exanthema in nearly one-third of females in one study, while this was rare with three days of treatment [<a href="#rid18">18</a>]. (See  <a class="medical medical_review" href="/z/d/html/83728.html" rel="external">"Hypersensitivity reactions to fluoroquinolones", section on 'Delayed maculopapular exanthema'</a>.)</p><p class="headingAnchor" id="H19048322"><span class="h2">Other types of immunologic reactions</span><span class="headingEndMark"> — </span>Two additional types of immunologic drug reactions that cannot be readily classified within the Gell and Coombs system are drug-induced autoimmunity and fixed drug eruption.</p><p class="headingAnchor" id="H19048348"><span class="h3">Drug-induced autoimmunity</span><span class="headingEndMark"> — </span>Drugs can induce autoimmune diseases [<a href="#rid48">48</a>]. Despite intensive scrutiny, the pathogenesis of these reactions has not been elucidated, although the finding that drug binding to HLA molecules can induce changes of the presented peptides has opened new pathways of research [<a href="#rid31">31,49</a>]. However, a definitive link between these findings and drug-induced autoimmune diseases has not yet been established.</p><p class="bulletIndent1"><span class="glyph">●</span>The best known example is a lupus-like disease, which can develop after exposure to <a class="drug drug_general" data-topicid="9813" href="/z/d/drug information/9813.html" rel="external">procainamide</a>, <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a>, <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">isoniazid</a>, <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">sulfasalazine</a>, <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a>, <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a>, and <a class="drug drug_general" data-topicid="9747" href="/z/d/drug information/9747.html" rel="external">penicillamine</a> [<a href="#rid48">48,50-52</a>]. (See  <a class="medical medical_review" href="/z/d/html/4677.html" rel="external">"Drug-induced lupus"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9747" href="/z/d/drug information/9747.html" rel="external">Penicillamine</a> can also cause a pemphigus-like disorder. (See  <a class="medical medical_review" href="/z/d/html/83684.html" rel="external">"Pathogenesis, clinical manifestations, and diagnosis of pemphigus", section on 'Drug exposure'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>IgA bullous dermatosis has been associated with <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a>  (<a class="graphic graphic_picture graphicRef77601" href="/z/d/graphic/77601.html" rel="external">picture 11</a>) and various other drugs, including <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a>, <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">ciprofloxacin</a>, and <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a>. (See  <a class="medical medical_review" href="/z/d/html/15301.html" rel="external">"Linear IgA bullous dermatosis"</a>.) </p><p></p><p class="headingAnchor" id="H19048354"><span class="h3">Fixed drug eruption</span><span class="headingEndMark"> — </span>Fixed drug eruption is a relatively common reaction, which is characterized by erythematous and edematous plaques with a grayish center or frank bullae. Lesions recur at exactly the same sites (typically lips and tongue, genitalia, face, and acral areas) with drug re-exposure  (<a class="graphic graphic_picture graphicRef52192" href="/z/d/graphic/52192.html" rel="external">picture 12</a> and <a class="graphic graphic_picture graphicRef65991" href="/z/d/graphic/65991.html" rel="external">picture 13</a>). These site(s) develop postinflammatory pigmentation. Fixed drug eruption can occur in response to sulfonamides, anticoagulants, and many other drugs [<a href="#rid53">53</a>]. The mechanism is unknown, although T cells residing in the skin produce interferon gamma [<a href="#rid54">54,55</a>]. (See  <a class="medical medical_review" href="/z/d/html/15760.html" rel="external">"Fixed drug eruption"</a>.)</p><p class="headingAnchor" id="H39"><span class="h1">PSEUDOALLERGIC REACTIONS</span><span class="headingEndMark"> — </span>Pseudoallergic drug reactions are adverse drug reactions with signs and symptoms that mimic immunologic drug allergies, but in which immunologic mechanisms have not been demonstrated  (<a class="graphic graphic_table graphicRef79967" href="/z/d/graphic/79967.html" rel="external">table 2</a>). They are a subset of type B drug hypersensitivity reaction (DHR) and are also called "nonimmune hypersensitivity reactions" [<a href="#rid7">7</a>]. (See <a class="local">'Categories of adverse drug reactions'</a> above.)</p><p>Pseudoallergic reactions are difficult to distinguish clinically because they are similar or identical in presentation to true allergic reactions. Some pseudoallergic reactions arise from direct (rather than immunologic) activation of immune and inflammatory cells, so the final steps in pathogenesis and the resultant clinical features are indistinguishable from those of allergic reactions. The complete mechanisms underlying most of them are not known and may differ from one another  (<a class="graphic graphic_table graphicRef79967" href="/z/d/graphic/79967.html" rel="external">table 2</a>).</p><p>A single receptor, known as MRGPRX2 (Mas-Related G-Protein Coupled Receptor Member X2) in humans and Mrgprb2 (Mas-Related G-Protein Coupled Receptor Member B2) in mice, was found to be crucial for IgE-independent, direct mast cell stimulation [<a href="#rid14">14</a>]. Fluoroquinolone antibiotics and neuromuscular blocking agents (NMBA) are known to bind to this receptor and to cause systemic, nonallergic (pseudoallergic, anaphylactoid) reactions via this mechanism. Some of the drugs listed below (common culprit drugs) may act via this mechanism. Why only some patients develop pseudoallergic symptoms is presently unclear.</p><p>Importantly, the diagnosis, prognosis, and prevention of pseudoallergy may be different from true allergic reactions. In particular, pseudoallergic reactions are not diagnosed with skin or in vitro allergy testing and do not worsen with repeated exposure. (See <a class="local">'Common culprit drugs'</a> below.)</p><p class="headingAnchor" id="H40"><span class="h2">Reactions that resemble anaphylaxis</span><span class="headingEndMark"> — </span>Idiosyncratic reactions that mimic IgE-mediated, type I allergic reactions are among the most important for clinicians to understand. Like IgE-mediated reactions, nonimmunologic activation of mast cells and basophils results in the release of vasoactive mediators. These pseudoallergic reactions range in severity from mild to fatal. Accordingly, acute nonimmunologic anaphylaxis should be treated in the same manner as immunologic anaphylaxis.</p><p>Nonimmunologic reactions resembling anaphylaxis are often referred to as "anaphylactoid." Unfortunately, the term anaphylactoid has been widely misinterpreted to mean a reaction that was similar to anaphylaxis but less severe, and has led to the undertreatment of patients with nonimmunologic anaphylaxis. Therefore, the term anaphylactoid is now discouraged, and the concept of nonimmunologic anaphylaxis is preferred. Clinicians should understand that all forms of anaphylaxis are potentially life threatening. (See  <a class="medical medical_review" href="/z/d/html/392.html" rel="external">"Anaphylaxis: Emergency treatment"</a>.)</p><p>It is unclear how certain drugs elicit these reactions. Some affected patients have underlying dermographism and seem to have an "instability" of their mast cells, which degranulate already upon pressure or by exposure to various small molecules.</p><p class="headingAnchor" id="H41"><span class="h3">Common culprit drugs</span><span class="headingEndMark"> — </span>Drugs that can cause nonimmunologic anaphylaxis are listed below, and the clinical syndromes associated with each are reviewed separately: </p><p class="bulletIndent1"><span class="glyph">●</span>Radiocontrast agents (see  <a class="medical medical_review" href="/z/d/html/2075.html" rel="external">"Diagnosis and treatment of an acute reaction to a radiologic contrast agent"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Opiates (see  <a class="medical medical_review" href="/z/d/html/2077.html" rel="external">"Perioperative anaphylaxis: Clinical manifestations, etiology, and management", section on 'Opioids'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nonsteroidal anti-inflammatory drugs (NSAIDs) (see  <a class="medical medical_review" href="/z/d/html/2082.html" rel="external">"NSAIDs (including aspirin): Allergic and pseudoallergic reactions"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">Vancomycin</a> (see  <a class="medical medical_review" href="/z/d/html/2083.html" rel="external">"Vancomycin hypersensitivity"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Local anesthetic agents (see  <a class="medical medical_review" href="/z/d/html/2084.html" rel="external">"Allergic reactions to local anesthetics"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chemotherapeutic agents (see  <a class="medical medical_review" href="/z/d/html/2835.html" rel="external">"Infusion reactions to systemic chemotherapy"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Monoclonal antibodies and other biologic therapies used in cancer therapy (see  <a class="medical medical_review" href="/z/d/html/2811.html" rel="external">"Infusion-related reactions to therapeutic monoclonal antibodies used for cancer therapy"</a>)</p><p></p><p class="headingAnchor" id="H6929968"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/87576.html" rel="external">"Patient education: Drug allergy (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H42"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Categories of adverse drug reactions</strong> – Adverse drug reactions may be broadly divided into types A and B  (<a class="graphic graphic_table graphicRef51797" href="/z/d/graphic/51797.html" rel="external">table 1</a>). Type A represent the majority of reactions, can affect any individual, and are predictable from the known pharmacologic properties of a drug. Type B reactions are less common, occur in susceptible patients, and usually cannot be predicted from the known pharmacologic properties of a drug. (See <a class="local">'Categories of adverse drug reactions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunologic/allergic reactions</strong> – Immunologic drug reactions, or allergic drug reactions, are a subset of type B reactions. Immunologic drug reactions are traditionally divided into four categories according to the Gell and Coombs system  (<a class="graphic graphic_table graphicRef80466" href="/z/d/graphic/80466.html" rel="external">table 3</a>). Types I and IV are far more common in clinical practice than types II and III (see <a class="local">'Classification of drug hypersensitivity'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Type I</strong> – Immediate in onset and mediated by IgE and mast cells/basophils.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Type II</strong> – Delayed in onset and caused by antibody (usually IgG) mediated cell destruction.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Type III</strong> – Delayed in onset and caused by IgG:drug immune complex deposition and complement activation.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Type IV</strong> – Delayed in onset and T cell mediated. Type IV reactions are further subdivided into types IVa, IVb, IVc, and IVd, depending on the other cell types involved  (<a class="graphic graphic_figure graphicRef75626" href="/z/d/graphic/75626.html" rel="external">figure 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Distinguishing among subtypes</strong> – Clinically, the different types of reactions have characteristic signs and symptoms, and the timing of onset of symptoms may also be helpful in distinguishing one type from another. However, there is significant clinical overlap among them. (See <a class="local">'Type I reactions'</a> above and <a class="local">'Type II reactions'</a> above and <a class="local">'Type III reactions'</a> above and <a class="local">'Type IV reactions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other immunologic reactions</strong> – Drug-induced autoimmunity and fixed drug eruption are other types of immunologic drug reactions that are not easily classified within the Gell and Coombs classification. (See <a class="local">'Other types of immunologic reactions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pseudoallergic reactions</strong> – Pseudoallergic drug reactions are a subset of type B (hypersensitivity) drug reactions with signs and symptoms that mimic immunologic drug allergies but are not immunologic. Pseudoallergic reactions are especially difficult to distinguish clinically because they can be similar or identical in presentation to true allergic reactions. However, the diagnosis, prognosis, and prevention of pseudoallergic reactions are different. (See <a class="local">'Pseudoallergic reactions'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279:1200.</a></li><li><a class="nounderline abstract_t">Lennard L. Implementation of TPMT testing. Br J Clin Pharmacol 2014; 77:704.</a></li><li><a class="nounderline abstract_t">Dern RJ, Beutler E, Alving AS. The hemolytic effect of primaquine V. Primaquine sensitivity as a manifestation of a multiple drug sensitivity. J Lab Clin Med 1981; 97:750.</a></li><li><a class="nounderline abstract_t">Lennard L, Van Loon JA, Weinshilboum RM. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 1989; 46:149.</a></li><li><a class="nounderline abstract_t">Pichler WJ. Immune pathomechanism and classification of drug hypersensitivity. Allergy 2019; 74:1457.</a></li><li><a class="nounderline abstract_t">Pichler WJ. Adverse side-effects to biological agents. Allergy 2006; 61:912.</a></li><li><a class="nounderline abstract_t">Johansson SG, Bieber T, Dahl R, et al. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol 2004; 113:832.</a></li><li><a class="nounderline abstract_t">Ben m'rad M, Leclerc-Mercier S, Blanche P, et al. Drug-induced hypersensitivity syndrome: clinical and biologic disease patterns in 24 patients. Medicine (Baltimore) 2009; 88:131.</a></li><li><a class="nounderline abstract_t">Pichler WJ, Adam J, Watkins S, et al. Drug Hypersensitivity: How Drugs Stimulate T Cells via Pharmacological Interaction with Immune Receptors. Int Arch Allergy Immunol 2015; 168:13.</a></li><li><a class="nounderline abstract_t">Pichler WJ, Thoo L, Yerly D. Drug hypersensitivity and eosinophilia: The decisive role of p-i stimulation. Allergy 2023; 78:2596.</a></li><li><a class="nounderline abstract_t">Yun J, Adam J, Yerly D, Pichler WJ. Human leukocyte antigens (HLA) associated drug hypersensitivity: consequences of drug binding to HLA. Allergy 2012; 67:1338.</a></li><li><a class="nounderline abstract_t">Johansson SG, Hourihane JO, Bousquet J, et al. A revised nomenclature for allergy. An EAACI position statement from the EAACI nomenclature task force. Allergy 2001; 56:813.</a></li><li><a class="nounderline abstract_t">Demoly P, Adkinson NF, Brockow K, et al. International Consensus on drug allergy. Allergy 2014; 69:420.</a></li><li><a class="nounderline abstract_t">McNeil BD, Pundir P, Meeker S, et al. Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions. Nature 2015; 519:237.</a></li><li><a class="nounderline abstract_t">Pichler WJ. Delayed drug hypersensitivity reactions. Ann Intern Med 2003; 139:683.</a></li><li><a class="nounderline abstract_t">Sachs B, Riegel S, Seebeck J, et al. Fluoroquinolone-associated anaphylaxis in spontaneous adverse drug reaction reports in Germany: differences in reporting rates between individual fluoroquinolones and occurrence after first-ever use. Drug Saf 2006; 29:1087.</a></li><li><a class="nounderline abstract_t">Manfredi M, Severino M, Testi S, et al. Detection of specific IgE to quinolones. J Allergy Clin Immunol 2004; 113:155.</a></li><li><a class="nounderline abstract_t">Schmid DA, Campi P, Pichler WJ. Hypersensitivity reactions to quinolones. Curr Pharm Des 2006; 12:3313.</a></li><li><a class="nounderline abstract_t">Johansson SG, Florvaag E, Oman H, et al. National pholcodine consumption and prevalence of IgE-sensitization: a multicentre study. Allergy 2010; 65:498.</a></li><li><a class="nounderline abstract_t">Birnbaum J, Vervloet D. Allergy to muscle relaxants. Clin Rev Allergy 1991; 9:281.</a></li><li><a class="nounderline abstract_t">Florvaag E, Johansson SG. The pholcodine story. Immunol Allergy Clin North Am 2009; 29:419.</a></li><li><a class="nounderline abstract_t">Chung CH, Mirakhur B, Chan E, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med 2008; 358:1109.</a></li><li><a class="nounderline abstract_t">Froehlich H, Verma R. Arthus reaction to recombinant hepatitis B virus vaccine. Clin Infect Dis 2001; 33:906.</a></li><li><a class="nounderline abstract_t">Relyveld EH, Bizzini B, Gupta RK. Rational approaches to reduce adverse reactions in man to vaccines containing tetanus and diphtheria toxoids. Vaccine 1998; 16:1016.</a></li><li><a class="nounderline abstract_t">Siegrist CA. Mechanisms underlying adverse reactions to vaccines. J Comp Pathol 2007; 137 Suppl 1:S46.</a></li><li><a class="nounderline abstract_t">Pichler WJ. Pharmacological interaction of drugs with antigen-specific immune receptors: the p-i concept. Curr Opin Allergy Clin Immunol 2002; 2:301.</a></li><li><a class="nounderline abstract_t">Clark RA, Chong B, Mirchandani N, et al. The vast majority of CLA+ T cells are resident in normal skin. J Immunol 2006; 176:4431.</a></li><li><a class="nounderline abstract_t">Schaerli P, Ebert L, Willimann K, et al. A skin-selective homing mechanism for human immune surveillance T cells. J Exp Med 2004; 199:1265.</a></li><li><a class="nounderline abstract_t">Storrs FJ. Contact dermatitis caused by drugs. Immunol Allergy Clin North Am 1991; 11:509.</a></li><li><a class="nounderline abstract_t">Pleasants RA, Walker TR, Samuelson WM. Allergic reactions to parenteral beta-lactam antibiotics in patients with cystic fibrosis. Chest 1994; 106:1124.</a></li><li><a class="nounderline abstract_t">Illing PT, Vivian JP, Dudek NL, et al. Immune self-reactivity triggered by drug-modified HLA-peptide repertoire. Nature 2012; 486:554.</a></li><li><a class="nounderline abstract_t">Hung SI, Chung WH, Liou LB, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A 2005; 102:4134.</a></li><li><a class="nounderline abstract_t">Lonjou C, Borot N, Sekula P, et al. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics 2008; 18:99.</a></li><li><a class="nounderline abstract_t">Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004; 428:486.</a></li><li><a class="nounderline abstract_t">Ding WY, Lee CK, Choon SE. Cutaneous adverse drug reactions seen in a tertiary hospital in Johor, Malaysia. Int J Dermatol 2010; 49:834.</a></li><li><a class="nounderline abstract_t">Locharernkul C, Loplumlert J, Limotai C, et al. Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population. Epilepsia 2008; 49:2087.</a></li><li><a class="nounderline abstract_t">Mehta TY, Prajapati LM, Mittal B, et al. Association of HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians. Indian J Dermatol Venereol Leprol 2009; 75:579.</a></li><li><a class="nounderline abstract_t">Ozeki T, Mushiroda T, Yowang A, et al. Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum Mol Genet 2011; 20:1034.</a></li><li><a class="nounderline abstract_t">McCormack M, Alfirevic A, Bourgeois S, et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med 2011; 364:1134.</a></li><li><a class="nounderline abstract_t">Zhang FR, Liu H, Irwanto A, et al. HLA-B*13:01 and the dapsone hypersensitivity syndrome. N Engl J Med 2013; 369:1620.</a></li><li><a class="nounderline abstract_t">Hershfield MS, Callaghan JT, Tassaneeyakul W, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing. Clin Pharmacol Ther 2013; 93:153.</a></li><li><a class="nounderline abstract_t">Spanou Z, Keller M, Britschgi M, et al. Involvement of drug-specific T cells in acute drug-induced interstitial nephritis. J Am Soc Nephrol 2006; 17:2919.</a></li><li><a class="nounderline abstract_t">Klemola E. Hypersensitivity reactions to ampicillin in cytomegalovirus mononucleosis. Scand J Infect Dis 1970; 2:29.</a></li><li><a class="nounderline abstract_t">Caubet JC, Kaiser L, Lemaître B, et al. The role of penicillin in benign skin rashes in childhood: a prospective study based on drug rechallenge. J Allergy Clin Immunol 2011; 127:218.</a></li><li><a class="nounderline abstract_t">Stamp LK, Taylor WJ, Jones PB, et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum 2012; 64:2529.</a></li><li><a class="nounderline abstract_t">Yun J, Mattsson J, Schnyder K, et al. Allopurinol hypersensitivity is primarily mediated by dose-dependent oxypurinol-specific T cell response. Clin Exp Allergy 2013; 43:1246.</a></li><li><a class="nounderline abstract_t">Messenheimer JA, Giorgi L, Risner ME. The tolerability of lamotrigine in children. Drug Saf 2000; 22:303.</a></li><li><a class="nounderline abstract_t">Uetrecht J. Current trends in drug-induced autoimmunity. Autoimmun Rev 2005; 4:309.</a></li><li><a class="nounderline abstract_t">Vergne P, Bertin P, Bonnet C, et al. Drug-induced rheumatic disorders: incidence, prevention and management. Drug Saf 2000; 23:279.</a></li><li><a class="nounderline abstract_t">Gait RC, Affleck AG, Leach IH, Varma S. Perinuclear antineutrophilic cytoplasmic antibody-positive polyarteritis nodosa secondary to minocycline treatment for acne vulgaris. J Am Acad Dermatol 2008; 58:S123.</a></li><li><a class="nounderline abstract_t">Li GC, Greenberg CS, Currie MS. Procainamide-induced lupus anticoagulants and thrombosis. South Med J 1988; 81:262.</a></li><li><a class="nounderline abstract_t">Sheikhzadeh A, Schäfer U, Schnabel A. Drug-induced lupus erythematosus by amiodarone. Arch Intern Med 2002; 162:834.</a></li><li><a class="nounderline abstract_t">Ozkaya E. Fixed drug eruption: state of the art. J Dtsch Dermatol Ges 2008; 6:181.</a></li><li><a class="nounderline abstract_t">Mizukawa Y, Shiohara T. Fixed drug eruption: a prototypic disorder mediated by effector memory T cells. Curr Allergy Asthma Rep 2009; 9:71.</a></li><li><a class="nounderline abstract_t">Shiohara T, Mizukawa Y. Fixed drug eruption: a disease mediated by self-inflicted responses of intraepidermal T cells. Eur J Dermatol 2007; 17:201.</a></li></ol></div><div id="topicVersionRevision">Topic 2086 Version 24.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9555760" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23962279" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Implementation of TPMT testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7229509" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The hemolytic effect of primaquine V. Primaquine sensitivity as a manifestation of a multiple drug sensitivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2758725" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30843233" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Immune pathomechanism and classification of drug hypersensitivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16867042" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Adverse side-effects to biological agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15131563" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19440116" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Drug-induced hypersensitivity syndrome: clinical and biologic disease patterns in 24 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26524432" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Drug Hypersensitivity: How Drugs Stimulate T Cells via Pharmacological Interaction with Immune Receptors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37395496" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Drug hypersensitivity and eosinophilia: The decisive role of p-i stimulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22943588" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Human leukocyte antigens (HLA) associated drug hypersensitivity: consequences of drug binding to HLA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11551246" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : A revised nomenclature for allergy. An EAACI position statement from the EAACI nomenclature task force.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24697291" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : International Consensus on drug allergy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25517090" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14568857" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Delayed drug hypersensitivity reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17061914" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Fluoroquinolone-associated anaphylaxis in spontaneous adverse drug reaction reports in Germany: differences in reporting rates between individual fluoroquinolones and occurrence after first-ever use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14713922" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Detection of specific IgE to quinolones.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17017926" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Hypersensitivity reactions to quinolones.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19796197" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : National pholcodine consumption and prevalence of IgE-sensitization: a multicentre study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1838298" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Allergy to muscle relaxants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19563989" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The pholcodine story.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18337601" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11512098" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Arthus reaction to recombinant hepatitis B virus vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9682353" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Rational approaches to reduce adverse reactions in man to vaccines containing tetanus and diphtheria toxoids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17559869" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Mechanisms underlying adverse reactions to vaccines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12130944" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Pharmacological interaction of drugs with antigen-specific immune receptors: the p-i concept.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16547281" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The vast majority of CLA+ T cells are resident in normal skin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15123746" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : A skin-selective homing mechanism for human immune surveillance T cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Contact dermatitis caused by drugs</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7924483" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Allergic reactions to parenteral beta-lactam antibiotics in patients with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22722860" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Immune self-reactivity triggered by drug-modified HLA-peptide repertoire.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15743917" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18192896" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15057820" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Medical genetics: a marker for Stevens-Johnson syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20618508" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Cutaneous adverse drug reactions seen in a tertiary hospital in Johor, Malaysia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18637831" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19915237" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Association of HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21149285" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21428769" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24152261" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : HLA-B*13:01 and the dapsone hypersensitivity syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23232549" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16943303" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Involvement of drug-specific T cells in acute drug-induced interstitial nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4329122" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Hypersensitivity reactions to ampicillin in cytomegalovirus mononucleosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21035175" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The role of penicillin in benign skin rashes in childhood: a prospective study based on drug rechallenge.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22488501" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24152157" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Allopurinol hypersensitivity is primarily mediated by dose-dependent oxypurinol-specific T cell response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10789824" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : The tolerability of lamotrigine in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15990079" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Current trends in drug-induced autoimmunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11051216" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Drug-induced rheumatic disorders: incidence, prevention and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18489046" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Perinuclear antineutrophilic cytoplasmic antibody-positive polyarteritis nodosa secondary to minocycline treatment for acne vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3124275" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Procainamide-induced lupus anticoagulants and thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11926860" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Drug-induced lupus erythematosus by amiodarone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18076661" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Fixed drug eruption: state of the art.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19063828" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Fixed drug eruption: a prototypic disorder mediated by effector memory T cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17478380" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Fixed drug eruption: a disease mediated by self-inflicted responses of intraepidermal T cells.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
